Looking for factors that predict outcomes in advanced skin lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at medical and disease details to find factors that can help predict how advanced mycosis fungoides or Sézary syndrome will behave. Your information may help doctors better estimate prognosis and plan care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced mycosis fungoides or Sézary syndrome (stages IIB to IVB).
- Your advanced-stage diagnosis was made within 6 months of your first visit to the study center.
- You plan to receive your ongoing care at this study center (or with the referring doctor) so follow-up information is available.
- You were not diagnosed as “early stage” before progressing to advanced stage.
- You were not diagnosed as advanced more than 6 months ago before coming to the study center.
- You are not only coming for a one-time consultation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for “predictive” and “prognostic” biomarkers—measurable signs in blood or tissue—to help predict how mycosis fungoides or Sézary syndrome will behave and how patients may respond to care. It may help doctors better understand outcomes for people with these skin lymphomas.
This trial tests a new drug called VG712 for people with a type of skin lymphoma called mycosis fungoides that has not responded to at least two previous treatments. The drug may help control the cancer, and the study will check if it is safe and effective.
This study looks at the long-term health of people who were diagnosed with a rare skin lymphoma (mycosis fungoides) or a related skin condition (lymphomatoid papulosis) before age 20. Researchers want to learn how these conditions affect people over time.
This Phase 2 study tests mogamulizumab together with low-dose total skin electron beam radiation to treat mycosis fungoides or Sézary syndrome, two types of skin lymphoma. It may help shrink skin disease and control symptoms by combining an immune-targeting medicine with skin-focused radiation.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This study tests a cream that targets inflammation in the skin for people with early-stage mycosis fungoides, a type of lymphoma. It may help relieve symptoms and slow the disease without stronger treatments.
Hear when a new Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.